Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease.

Literature DB >> 28096071

Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease.

Ambrogio Orlando¹, Rosalba Orlando¹, Francesco Ciccia², Sara Renna¹, Aroldo Rizzo³, Mario Cottone¹, Fabio Salvatore Macaluso¹.

Abstract

Entities: Chemical Disease Species

Keywords: Spondyloarthritis; T Cells; Treatment

Mesh：

Substances：

Year: 2017 PMID： 28096071 DOI： 10.1136/annrheumdis-2016-211011

Source DB: PubMed Journal: Ann Rheum Dis ISSN： 0003-4967 Impact factor: 19.103

Keyword Cloud
Cited

× No keyword cloud information.

8 in total

1. Vedolizumab-Induced De Novo Extraintestinal Manifestations.

Authors: Liege I Diaz; Tara Keihanian; Ingrid Schwartz; Su Bin Kim; Fernando Calmet; Maria Alejandra Quintero; Maria T Abreu
Journal: Gastroenterol Hepatol (N Y) Date: 2020-02

Review 2. The balance of power: innate lymphoid cells in tissue inflammation and repair.

Authors: Jim G Castellanos; Randy S Longman
Journal: J Clin Invest Date: 2019-06-10 Impact factor: 14.808

3. The Association Between Arthralgia and Vedolizumab Using Natural Language Processing.

Authors: Tianrun Cai; Tzu-Chieh Lin; Allison Bond; Jie Huang; Gwendolyn Kane-Wanger; Andrew Cagan; Shawn N Murphy; Ashwin N Ananthakrishnan; Katherine P Liao
Journal: Inflamm Bowel Dis Date: 2018-09-15 Impact factor: 5.325

Review 4. Revisiting the gut-joint axis: links between gut inflammation and spondyloarthritis.

Authors: Eric Gracey; Lars Vereecke; Dermot McGovern; Mareike Fröhling; Georg Schett; Silvio Danese; Martine De Vos; Filip Van den Bosch; Dirk Elewaut
Journal: Nat Rev Rheumatol Date: 2020-07-13 Impact factor: 20.543

5. Assessment of extraintestinal manifestations in inflammatory bowel diseases: A systematic review and a proposed guide for clinical trials.

Authors: Lucas Guillo; Ferdinando D'Amico; Mélanie Serrero; Karine Angioi; Damien Loeuille; Antonio Costanzo; Silvio Danese; Laurent Peyrin-Biroulet
Journal: United European Gastroenterol J Date: 2020-08-10 Impact factor: 4.623

Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease.

1. Vedolizumab-Induced De Novo Extraintestinal Manifestations.

Review 2. The balance of power: innate lymphoid cells in tissue inflammation and repair.

3. The Association Between Arthralgia and Vedolizumab Using Natural Language Processing.

Review 4. Revisiting the gut-joint axis: links between gut inflammation and spondyloarthritis.

5. Assessment of extraintestinal manifestations in inflammatory bowel diseases: A systematic review and a proposed guide for clinical trials.

Review 6. Bedside to bench: defining the immunopathogenesis of psoriatic arthritis.

Review 7. The gut-joint axis in spondyloarthritis: immunological, microbial, and clinical insights.

Review 8. Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease.